You are looking at the summary.
See the full textSummary
Antibiotics face an unfortunate paradox: While we desperately need new drugs to fight against the growing threat of resistant bacteria, their discovery and development has ground to a crawl. A series of financial setbacks, scientific and regulatory pushed companies in the field, and most investors who could help get new drug candidates to the clinic are skeptical that these drugs can be profitable. Now some are heralding new signs of life, including the return of some pharmaceutical superpowers. But desperate moves by governments to encourage companies and researchers are sufficiently in spring the next generation of antibiotics from the lab?
0 Komentar